Comparative study of chitosan- and PEG-coated lipid and PLGA nanoparticles as oral delivery systems for cannabinoids
Source abstract
Abstract
The cannabinoid derivative 1-naphthalenyl[4-(pentyloxy)-1-naphthalenyl]methanone (CB13) has an important therapeutic potential as analgesic in chronic pain states that respond poorly to conventional drugs. However, the incidence of its mild-to-moderate and dose-dependent adverse effects, as well as its pharmacokinetic profile, actually holds back its use in humans. Thus, the use of a suitable carrier system for oral delivery of CB13 becomes an attractive strategy to develop a valuable therapy. Polymeric poly(lactic-co-glycolic) acid (PLGA) and lipid nanoparticles (LNPs) are widely studied delivery vehicles that improve the bioavailability of lipophilic compounds and present special interest in oral delivery. Their surface can be modified to improve the adhesion of particles to the oral mucosa and increase their circulation time in blood with additives such as chitosan (CS) and polyethylene glycol (PEG), which can be feasibly incorporated onto these particles in a post-production step. In this work, CS- and PEG-modified polymeric PLGA and LNPs were successfully obtained and comparatively evaluated under the same experimental conditions as oral carriers for CB13. All the formulations presented adequate blood compatibility and absence of cytotoxicity in Caco-2 cells. Coating with CS led to a higher interaction with Caco-2 cells and a limited uptake in THP1 cells, while coating with PEG led to a limited uptake in Caco-2 cells and strongly prevented THP1 cells uptake. The performance of each formulation is discussed as a comparison of the potential of these carriers as oral delivery systems of CB13.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Cannabis and Cannabinoid Research · Advanced Drug Delivery Systems · Advancements in Transdermal Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (64)
Show source-provided references
1. Alhamoruni A, Lee AC, Wright KL, Larvin M, O’Sullivan SE (2010) Pharmacological effects of cannabinoids on the Caco-2 cell culture model of intestinal permeability. J Pharmacol Exp Ther 335:92–10210.1124/jpet.110.168237 ↗
2. Almeida AJ, Souto E (2007) Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev 59:478–49010.1016/j.addr.2007.04.007 ↗
3. Alvarez-Fuentes J, Martin-Banderas L, Munoz-Rubio I, Holgado MA, Fernandez-Arevalo M (2012) Development and validation of an RP-HPLC method for CB13 evaluation in several PLGA nanoparticle systems. Sci World J. doi: 10.1100/2012/737526
4. Attal N, Brasseur L, Guirimand D, Clermond-Griamien S, Atlami S, Bouhassira D (2004) Are oral cannabinoids safe and effective in refractory neuropathic pain? Eur J Pain 8:173–17710.1016/S1090-3801(03)00084-3 ↗
5. Ben Amar M (2006) Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol 105:1–2510.1016/j.jep.2006.02.001 ↗
6. Bocca C, Caputo O, Cavalli RB, Gabriel L, Miglietta A, Gasco MR (1998) Phagocytic uptake of fluorescent stealth and non-stealth solid lipid nanoparticles. Int J Pharm 175:185–19310.1016/S0378-5173(98)00282-8 ↗
7. Chakravarthi SS, Robinson DH (2011) Enhanced cellular association of paclitaxel delivered in chitosan-PLGA particles. Int J Pharm 409:111–12010.1016/j.ijpharm.2011.02.034 ↗
8. Das S, Chaudhury A (2011) Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech 12:62–7610.1208/s12249-010-9563-0 ↗
9. Date AA, Joshi MD, Patravale VB (2007) Parasitic diseases: liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv Drug Deliv Rev 59:505–52110.1016/j.addr.2007.04.009 ↗
10. des Rieux A, Fievez V, Garinot M, Schneider Y, Preat V (2006) Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Controlled Release 116:1–2710.1016/j.jconrel.2006.08.013 ↗
11. Durán-Lobato M, Muñoz-Rubio I, Holgado MÁ, Álvarez-Fuentes J, Fernández-Arévalo M, Martín-Banderas L (2014) Enhanced cellular uptake and biodistribution of a synthetic cannabinoid loaded in surface-modified poly(lactic-co-glycolic acid) nanoparticles. J Biomed Nanotechnol 10:1068–107910.1166/jbn.2014.1806 ↗
12. Dziadulewicz EK, Bevan SJ, Brain CT, Coote PR, Culshaw AJ, Davis AJ, Edwards LJ, Fisher AJ, Fox AJ, Gentry C, Groarke A, Hart TW, Huber W, James LF, Kesingland A, La Vecchia L, Loong Y, Lyothier I, McNair K, O’Farrell C, Peacock M, Portmann R, Schopfer U, Yaqoob M, Zadrobilek J (2007) Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration. J Med Chem 50:3851–385610.1021/jm070317a ↗
13. Fricker G, Kromp T, Wendel A, Blume A, Zirkel J, Rebmann H, Setzer C, Quinkert R, Martin F, Mueller-Goymann C (2010) Phospholipids and lipid-based formulations in oral drug delivery. Pharm Res 27:1469–148610.1007/s11095-010-0130-x ↗
14. Froehlich E (2012) The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int J Nanomed 7:5577–559110.2147/IJN.S36111 ↗
15. Garcia-Fuentes M, Prego C, Torres D, Alonso MJ (2005) A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as carriers for oral calcitonin delivery. Eur J Pharm Sci 25:133–14310.1016/j.ejps.2005.02.008 ↗
16. Gardin A, Kucher K, Kiese B, Appel-Dingemanse S (2009) Cannabinoid receptor agonist 13, a novel cannabinoid agonist: first in human pharmacokinetics and safety. Drug Metab Dispos 37:827–83310.1124/dmd.108.024000 ↗
17. Garinot M, Fievez V, Pourcelle V, Stoffelbach F, des Rieux A, Plapied L, Theate I, Freichels H, Jerome C, Marchand-Brynaert J, Schneider Y, Preat V (2007) PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination. J Controlled Release 120:195–20410.1016/j.jconrel.2007.04.021 ↗
18. Gref R, Luck M, Quellec P, Marchand M, Dellacherie E, Harnisch S, Blunk T, Muller RH (2000) ‘Stealth’ corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B 18:301–31310.1016/S0927-7765(99)00156-3 ↗
19. Gustafsson SB, Lindgren T, Jonsson M, Jacobsson SOP (2009) Cannabinoid receptor-independent cytotoxic effects of cannabinoids in human colorectal carcinoma cells: synergism with 5-fluorouracil. Cancer Chemother Pharmacol 63:691–70110.1007/s00280-008-0788-5 ↗
20. Hall W, Solowij N (1998) Adverse effects of cannabis. Lancet 352:1611–161610.1016/S0140-6736(98)05021-1 ↗
21. Harde H, Das M, Jain S (2011) Solid lipid nanoparticles: an oral bioavailability enhancer vehicle. Expert Opin Drug Deliv 8:1407–142410.1517/17425247.2011.604311 ↗
22. Hart S, Fischer OM, Ullrich A (2004) Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res 64:1943–195010.1158/0008-5472.CAN-03-3720 ↗
23. Hoffart V, Ubrich N, Simonin C, Babak V, Vigneron C, Hoffman M, Lecompte T, Maincent P (2002) Low molecular weight heparin-loaded polymeric nanoparticles: formulation, characterization, and release characteristics. Drug Dev Ind Pharm 28:1091–109910.1081/DDC-120014576 ↗
24. Hombreiro-Perez M, Siepmann J, Zinutti C, Lamprecht A, Ubrich N, Hoffman M, Bodmeier R, Maincent P (2003) Non-degradable microparticles containing a hydrophilic and/or a lipophilic drug: preparation, characterization and drug release modeling. J Controlled Release 88:413–42810.1016/S0168-3659(03)00030-0 ↗
25. Issa MM, Koping-Hoggard M, Artursson P (2005) Chitosan and the mucosal delivery of biotechnology drugs. Drug Discovery Today 2:1–610.1016/j.ddtec.2005.05.008 ↗
26. Iversen L, Chapman V (2002) Cannabinoids: a real prospect for pain relief? Curr Opin Pharmacol 2:50–5510.1016/S1471-4892(01)00120-5 ↗
27. Kassim A, Mahmud HE, Yee LM, Hanipah N (2006) Electrochemical preparation and characterization of polypyrrole-polyethylene glycol conducting polymer composite films. Pac J Sci Technol 7:103–107
28. Knop K, Hoogenboom R, Fischer D, Schubert US (2010) Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed 49:6288–630810.1002/anie.200902672 ↗
29. Ligresti A, Bisogno T, Matias I, De Petrocellis L, Cascio MG, Cosenza V, D’Argenio G, Scaglione G, Bifulco M, Sorrentini I, Di Marzo V (2003) Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 125:677–68710.1016/S0016-5085(03)00881-3 ↗
30. Lopes R, Eleuterio CV, Goncalves LMD, Cruz MEM, Almeida AJ (2012a) Lipid nanoparticles containing oryzalin for the treatment of leishmaniasis. Eur J Pharm Sci 45:442–45010.1016/j.ejps.2011.09.017 ↗
31. Lopes RM, Luisa Corvo M, Eleuterio CV, Carvalheiro MC, Scoulica E, Cruz MEM (2012b) Formulation of oryzalin (ORZ) liposomes: in vitro studies and in vivo fate. Eur J Pharm Biopharm 82:281–29010.1016/j.ejpb.2012.06.013 ↗
32. Lopez-Rodriguez ML, Viso A, Ortega-Gutierrez S, Diaz-Laviada I (2005) Involvement of cannabinoids in cellular proliferation. Mini Rev Med Chem 5:97–10610.2174/1389557053402819 ↗
33. Lunov O, Syrovets T, Loos C, Beil J, Delecher M, Tron K, Nienhaus GU, Musyanovych A, Mailaender V, Landfester K, Simmet T (2011) Differential uptake of functionalized polystyrene nanoparticles by human macrophages and a monocytic cell line. ACS Nano 5:1657–166910.1021/nn2000756 ↗
34. Martin-Banderas L, Alvarez-Fuentes J, Duran-Lobato M, Prados J, Melguizo C, Fernandez-Arevalo M, Angeles Holgado M (2012) Cannabinoid derivate-loaded PLGA nanocarriers for oral administration: formulation, characterization, and cytotoxicity studies. Int J Nanomed 7:5793–5806
35. Martin-Banderas L, Duran-Lobato M, Munoz-Rubio I, Alvarez-Fuentes J, Fernandez-Arevalo M, Holgado MA (2013a) Functional PLGA NPs for oral drug delivery: recent strategies and developments. Mini Rev Med Chem 13:58–6910.2174/138955713804484721 ↗
36. Martin-Banderas L, Saez-Fernandez E, Angeles Holgado M, Matilde Duran-Lobato M, Prados JC, Melguizo C, Arias JL (2013b) Biocompatible gemcitabine-based nanomedicine engineered by Flow Focusing (R) for efficient antitumor activity. Int J Pharm 443:103–10910.1016/j.ijpharm.2012.12.048 ↗
37. Nafee N, Schneider M, Schaefer UF, Lehr C (2009) Relevance of the colloidal stability of chitosan/PLGA nanoparticles on their cytotoxicity profile. Int J Pharm 381:130–13910.1016/j.ijpharm.2009.04.049 ↗
38. Owens D, Peppas N (2006) Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 307:93–10210.1016/j.ijpharm.2005.10.010 ↗
39. Pappo J, Ermak TH (1989) Uptake and translocation of fluorescent latex-particles by rabbit peyers patch follicle epithelium—a quantitative model for M cell uptake. Clin Exp Immunol 76:144–148
40. Parhi R, Suresh P (2010) Production of solid lipid nanoparticles—drug loading and release mechanism. J Chem Pharm Res 2(1):211–227
41. Parveen S, Sahoo SK (2011) Long circulating chitosan/PEG blended PLGA nanoparticle for tumor drug delivery. Eur J Pharmacol 670:372–38310.1016/j.ejphar.2011.09.023 ↗
42. Patel B, Gupta V, Ahsan F (2012) PEG-PLGA based large porous particles for pulmonary delivery of a highly soluble drug, low molecular weight heparin. J Controlled Release 162:310–32010.1016/j.jconrel.2012.07.003 ↗
43. Pedersen N, Hansen S, Heydenreich AV, Kristensen HG, Poulsen HS (2006) Solid lipid nanoparticles can effectively bind DNA, streptavidin and biotinylated ligands. Eur J Pharm Biopharm 62:155–16210.1016/j.ejpb.2005.09.003 ↗
44. Pertwee RG (2001) Cannabinoid receptors and pain. Prog Neurobiol 63:569–61110.1016/S0301-0082(00)00031-9 ↗
45. Petrova S, Miloshev S, Mateva R, Iliev I (2008) Synthesis of Amphiphilic PEG-PCL-PEG triblock copolymers. J Univ Chem Technol Metall 43:199–204
46. Reitz C, Strachan C, Kleinebudde P (2008) Solid lipid extrudates as sustained-release matrices: the effect of surface structure on drug release properties. Eur J Pharm Sci 35:335–34310.1016/j.ejps.2008.08.002 ↗
47. Sarmento B, Mazzaglia D, Bonferoni MC, Patricia Neto A, MdC Monteiro, Seabra V (2011) Effect of chitosan coating in overcoming the phagocytosis of insulin loaded solid lipid nanoparticles by mononuclear phagocyte system. Carbohydr Polym 84:919–92510.1016/j.carbpol.2010.12.042 ↗
48. Sarne Y, Asaf F, Fishbein M, Gafni M, Keren O (2011) The dual neuroprotective-neurotoxic profile of cannabinoid drugs. Br J Pharmacol 163:1391–140110.1111/j.1476-5381.2011.01280.x ↗
49. Semete B, Booysen L, Kalombo L, Ramalapa B, Hayeshi R, Swai HS (2012) Effects of protein binding on the biodistribution of PEGylated PLGA nanoparticles post oral administration. Int J Pharm 424:115–12010.1016/j.ijpharm.2011.12.043 ↗
50. Shen H, Hu X, Yang F, Bei J, Wang S (2011) Cell affinity for bFGF immobilized heparin-containing poly(lactide-co-glycolide) scaffolds. Biomaterials 32:3404–341210.1016/j.biomaterials.2011.01.037 ↗
51. Singh R, Lillard JW Jr (2009) Nanoparticle-based targeted drug delivery. Exp Mol Pathol 86:215–22310.1016/j.yexmp.2008.12.004 ↗
52. Tabatt K, Sameti M, Olbrich C, Muller RH, Lehr CM (2004) Effect of cationic lipid and matrix lipid composition on solid lipid nanoparticle-mediated gene transfer. Eur J Pharm Biopharm 57:155–16210.1016/j.ejpb.2003.10.015 ↗
53. Tobio M, Gref R, Sanchez A, Langer R, Alonso MJ (1998) Stealth PLA-PEG nanoparticles as protein carriers for nasal administration. Pharm Res 15:270–27510.1023/A:1011922819926 ↗
54. Tobío M, Sanchez A, Vila A, Soriano I, Evora C, Vila-Jato J, Alonso M (2000) The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Colloids Surf B 18:315–32310.1016/S0927-7765(99)00157-5 ↗
55. Vila A, Sanchez A, Tobio M, Calvo P, Alonso M (2002) Design of biodegradable particles for protein delivery. J Controlled Release 78:15–2410.1016/S0168-3659(01)00486-2 ↗
56. Vila A, Gill H, McCallion O, Alonso MJ (2004) Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density. J Controlled Release 98:231–24410.1016/j.jconrel.2004.04.026 ↗
57. Vila A, Sánchez A, Évora C, Soriano I, McCallion O, Alonso MJ (2005) PLA-PEG particles as nasal protein carriers: the influence of the particle size. Int J Pharm 292:43–5210.1016/j.ijpharm.2004.09.002 ↗
58. Vonarbourg A, Passirani C, Saulnier P, Benoit J (2006) Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials 27:4356–437310.1016/j.biomaterials.2006.03.039 ↗
59. Wang Q, Dong Z, Du Y, Kennedy JF (2007) Controlled release of ciprofloxacin hydrochloride from chitosan/polyethylene glycol blend films. Carbohydr Polym 69:336–34310.1016/j.carbpol.2006.10.014 ↗
60. Yang A, Liu W, Yang X (2012) Serum proteins opsonization and phagocytic uptake of PEG-modified PLGA nanoparticles: effect of particle size. Biotechnol Chem Mater Eng, Pts 1-3 393–395:939–942
61. Zhang ZP, Feng SS (2006a) The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles. Biomaterials 27:4025–403310.1016/j.biomaterials.2006.03.006 ↗
62. Zhang Z, Feng S (2006b) Self-assembled nanoparticles of poly(lactide)—vitamin E TPGS copolymers for oral chemotherapy. Int J Pharm 324:191–19810.1016/j.ijpharm.2006.06.013 ↗
63. Zhang X, Sun M, Zheng A, Cao D, Bi Y, Sun J (2012) Preparation and characterization of insulin-loaded bioadhesive PLGA nanoparticles for oral administration. Eur J Pharm Sci 45:632–63810.1016/j.ejps.2012.01.002 ↗
64. Zhang L, Wang S, Zhang M, Sun J (2013) Nanocarriers for oral drug delivery. J Drug Target 21:515–52710.3109/1061186X.2013.789033 ↗